Minimum Effective Volume of Lidocaine Costoclavicular Brachial Plexus Block

Minimum Effective Volume of Lidocaine for Ultrasound-Guided Costoclavicular Infraclavicular Brachial Plexus Block

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02932670

Enrollment

Registered

2016-10-13

Start date

2016-10-31

Completion date

2017-02-28

Last updated

2017-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Upper Extremity Surgery

Brief summary

The aim of this study is to determine the minimum effective volume of lidocaine in 90% of patients (ED90) required for single-injection US-guided costoclavicular infraclavicular.

Detailed description

The aim of this study is to determine the minimum effective volume of lidocaine in 90% of patients (ED90) required for single-injection US-guided costoclavicular ICB. Determination of the minimum effective volume of LA is important because it prevents the administration of an unnecessarily large (and potentially toxic) dose. Furthermore, when multiple blocks need to be performed at the same time in the same patient, knowledge of the minimum effective volume allows to the operator to preserve efficacy without sacrificing safety for each block.

Interventions

OTHERcostoclavicular nerve block

ultrasound-guided costoclavicular nerve block

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* age between 18 and 70 years * American Society of Anesthesiologists classification 1-3 * body mass index between 20 and 30

Exclusion criteria

* adults who are unable to give their own consent * pre-existing neuropathy (assessed by history and physical examination) * coagulopathy (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. platelets≤ 100, International Normalized Ratio≥ 1.4 or partial prothrombin time ≥ 50) * renal failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. creatinine≥ 100) * hepatic failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. transaminases≥ 100) * allergy to local anesthetics * pregnancy * prior surgery in the infraclavicular region * chronic pain syndromes requiring opioid intake at home

Design outcomes

Primary

Measure	Time frame	Description
success rate	0-30 min	minimal composite score of 14 out of 16

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026